MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Inclusion Criteria:

All subjects:

* Pathologically confirmed diagnosis of solid tumors
* Metastatic disease
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1
* Adequate bone marrow, hepatic and renal function
* Normal Electrocardiogram (ECG)
* 18 years of age or above
* Able to understand and sign informed consent

Pilot study only:

\- CRC, TNBC, ER/PR Breast Cancer, NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal Junction (GEJ) adenocarcinoma, Head and Neck Cancer

Expansion Phase Additional Criteria:

* Locally advanced or metastatic breast cancer
* Received at least one cytotoxic therapy in the locally advanced and metastatic setting
* Received ≤ 5 prior lines of chemotherapy in the metastatic setting
* Candidate for chemotherapy

Expansion Phase Cohort 3 additional inclusion criteria:

* Breast cancer with active brain metastasis
* Neurologically stable

Exclusion Criteria:

* Active Central nervous system (CNS) metastasis (applies to pilot phase and expansion phase cohort 1 and 2 only)
* Clinically significant GI disorders
* Prior irinotecan or bevacizumab therapy within last 6 months and for Expansion Phase patients, have received any prior treatment with Topol inhibitor
* Known hypersensitivity to MM-398 or ferumoxytol
* Inability to undergo MRI
* Active infection
* Pregnant or breast feeding
* Prior chemotherapy administered within 3 weeks, or within a time interval less than at least 5 half-lives of the agent, whichever is longer, prior to the first scheduled day of dosing in this study
* Received radiation therapy in the last 14 days
* Treated with parenteral iron in the previous 4 weeks